Company Filing History:
5 out of 5 
1 out of 832,843 Years Active: 2014-2019
Title: Innovations by George Rodeheaver: A Pioneer in Microbial Treatments
Introduction
George Rodeheaver, based in Charlottesville, VA, is an accomplished inventor with a notable portfolio of six patents. His expertise lies in developing compositions and methods aimed at treating microbial infections, which demonstrate significant potential in healthcare applications.
Latest Patents
Rodeheaver's latest innovations include groundbreaking patents such as "Compositions and Methods of Treating Microbes." This invention discloses unique compositions designed to treat microbial infections and promote wound healing. Notably, the methods consider specific types of microbial challenges, including biofilms. His findings suggest that the compositions may include at least one surface-active agent, categorized as anionic, cationic, non-ionic, or a combination of these agents. Another significant patent, "Compositions for Treating Biofilms and Methods for Using Same," describes formulations containing a surface-active agent and a sub-lethal amount of an antimicrobial agent, providing promising solutions for tackling biofilm-related complications.
Career Highlights
Rodeheaver has made substantial contributions to his field through his work at Plurogen Therapeutics, Inc., a company dedicated to therapeutic innovations. His experience in the pharmaceutical sector has equipped him with the tools to successfully navigate the complexities of patent applications and the commercialization of inventions.
Collaborations
Throughout his career, Rodeheaver has collaborated with notable professionals, including Adam J Katz and Neal Koller. These partnerships have likely fostered an environment of innovation and cross-disciplinary advancements in microbial treatment technologies.
Conclusion
George Rodeheaver stands out as a pivotal inventor in the realm of microbial treatment innovations. His patents not only contribute to the scientific community but also hold the potential to significantly improve therapeutic outcomes for patients suffering from microbial infections.